These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. 2 new drugs for weight loss. Med Lett Drugs Ther; 2012 Sep; 54(1398):69-71. PubMed ID: 22992487 [No Abstract] [Full Text] [Related]
4. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease. Bays H Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765 [TBL] [Abstract][Full Text] [Related]
5. High demand likely for prescription weight-control drugs. Mayo Clin Health Lett; 2012 Nov; 30(11):4. PubMed ID: 23795359 [No Abstract] [Full Text] [Related]
6. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss. Kelly EM; Tungol AA; Wesolowicz LA J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010 [TBL] [Abstract][Full Text] [Related]
7. Phentermine: an appetite-suppressant amphetamine classified as a narcotic in France. Is a combination with topiramate on the horizon? Prescrire Int; 2012 Sep; 21(130):209. PubMed ID: 23016252 [TBL] [Abstract][Full Text] [Related]
8. Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out. Citrome L Int J Clin Pract; 2014 Dec; 68(12):1401-5. PubMed ID: 25418525 [No Abstract] [Full Text] [Related]
9. Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird. Rubio MA Endocrinol Nutr; 2014 Dec; 61(10):501-4. PubMed ID: 25434595 [No Abstract] [Full Text] [Related]
10. The pharmacological and surgical management of adults with obesity. Ryan DH J Fam Pract; 2014 Jul; 63(7 Suppl):S21-6. PubMed ID: 25198216 [No Abstract] [Full Text] [Related]
11. Fixed-dose combination of phentermine-topiramate for the treatment of obesity. Halpern B; Faria AM; Halpern A Expert Rev Clin Pharmacol; 2013 May; 6(3):235-41. PubMed ID: 23656337 [TBL] [Abstract][Full Text] [Related]
12. Lemons for obesity. Lauer MS Ann Intern Med; 2012 Jul; 157(2):139-40. PubMed ID: 22801677 [No Abstract] [Full Text] [Related]
13. Two anti-obesity hopefuls and their safety. Bello NT; Campbell SC Expert Opin Drug Saf; 2012 Sep; 11(5):681-3. PubMed ID: 22788876 [No Abstract] [Full Text] [Related]
15. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia). Shyh G; Cheng-Lai A Cardiol Rev; 2014; 22(1):43-50. PubMed ID: 24304809 [TBL] [Abstract][Full Text] [Related]
16. The FDA's assessment of two drugs for chronic weight management. Colman E; Golden J; Roberts M; Egan A; Weaver J; Rosebraugh C N Engl J Med; 2012 Oct; 367(17):1577-9. PubMed ID: 23050510 [No Abstract] [Full Text] [Related]
18. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Garvey WT; Ryan DH; Look M; Gadde KM; Allison DB; Peterson CA; Schwiers M; Day WW; Bowden CH Am J Clin Nutr; 2012 Feb; 95(2):297-308. PubMed ID: 22158731 [TBL] [Abstract][Full Text] [Related]
19. New developments in the pharmacologic treatment of obesity. Fantasia HC Nurs Womens Health; 2013; 17(1):53-62. PubMed ID: 23399013 [TBL] [Abstract][Full Text] [Related]
20. Obesity Epidemic: Pharmaceutical Weight Loss. Curry SA R I Med J (2013); 2017 Mar; 100(2):18-20. PubMed ID: 28246654 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]